COMMUNIQUÉS West-GlobeNewswire

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
04/06/2025
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from [...]
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
04/06/2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
04/06/2025
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirement NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“ [...]
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
04/06/2025
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically [...]
The Joint Corp. Appoints Sandi Karrmann as Director
04/06/2025
- Accomplished Global HR Executive with Deep Franchise and Healthcare Expertise, including CHRO Roles at Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International, to Join Board - SCOTTSDALE, Ariz., June 04, [...]
Ex dividend NOK 1.25 today
04/06/2025
The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025.
Ose Immunotherapeutics : Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 25 juin 2025
04/06/2025
Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 25 juin 2025 Nantes, le 4 juin 2025, 8 heures – OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnémo: OSE) annonce la mise en ligne des [...]
Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
04/06/2025
Documents made available to the shareholders for the combined general meeting of June 25 th , 2025 Nantes, June 4 th , 2025, 8 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE) announces the publication [...]
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
04/06/2025
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des programmes clés dans l'inflammation et de l'immuno-oncologie
04/06/2025
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des programmes clés dans l'inflammation et de l'immuno-oncologie Insuffler un nouvel élan en immunologie et inflammation grâce au développement [...]
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
04/06/2025
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab development, [...]
Philips to repurchase up to 6 million shares to cover long-term incentive plans
04/06/2025
June 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive [...]
Molecular Health and Axxam enter into a strategic partnership to bolster the discovery of innovative targets in drug development
04/06/2025
Pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companies MILAN, Italy and HEIDELBERG, Germany, June 04, 2025 (GLOBE [...]
More Than a Symposium: IOF Builds Momentum Toward the Future of Orthodontics
04/06/2025
HONG KONG, June 03, 2025 (GLOBE NEWSWIRE) -- The International Orthodontics Foundation (IOF), in collaboration with the ADA Forsyth Institute (AFI) and the Complutense University of Madrid (UCM), will host the 2025 IOF- [...]
Merus N.V. Announces Pricing of Public Offering of Common Shares
04/06/2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific [...]
Des institutions mondiales de renom et IBA lancent la Proton Therapy Academy pour élaborer l'avenir des soins contre le cancer
04/06/2025
Nouvelle initiative mondiale de formation présentée lors de la conférence annuelle PTCOG 2025 Louvain-la-Neuve, Belgique, le 4 juin 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d [...]
World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care
04/06/2025
New global education initiative unveiled at 2025 PTCOG Annual Conference Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s [...]
Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction
04/06/2025
Saint-Herblain (France), le 4 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA) (la « Société »), société spécialisée dans les vaccins, a annoncé aujourd’hui la mise à disposition des documents préparatoires [...]
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
04/06/2025
Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“ [...]

Pages